Clinical research organisation CILcare and non-profit translational research institute CBSET have partnered with technology development firm Charles Stark Draper Laboratory to assess a new intracochlear drug delivery (ICDD) device for the treatment of congenital and degenerative hearing loss.
Developed by Draper, the ICDD device maintains an accurate and constant volume of the inner ear fluid, facilitated by its infuse-withdraw cycles.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataThe device is designed to ensure precise and direct administration of an intracochlear drug with effective distribution of each dose and without causing damage to sensitive hearing structures.
The organisations intend to evaluate the device using CILcare’s preclinical models for hearing loss with operational support from CBSET’s facility for preclinical research and development.
CILcare CEO Célia Belline said: “The alliance between CILcare, the world’s leading services company in ear disorders and Draper’s expertise in biomedical solutions, will allow us to develop a new generation of treatments to cure hearing loss.
“The intracochlear drug delivery device is revolutionising the treatment of inner ear diseases by circumventing the tissue permeation barriers that have long hampered the development of pharmacotherapies for hearing disorders.”
CILcare is currently working towards bolstering the partnership and testing the device with drug candidates by forming an industry consortium of biopharmaceutical firms that develop compounds related to the therapeutic area.
The primary focus of the consortium is to provide the partnered firms with proof-of-concept data on the ICDD’s efficacy for delivering their compounds in animal models, before proceeding to human clinical trials.
